Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases.
It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.
The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV).
In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV.
The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014.
Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 6, 24 | -1.51 Decreased by -459.26% | -2.02 Increased by +25.25% |
| Aug 8, 24 | -2.05 Decreased by -540.62% | -2.23 Increased by +8.07% |
| May 8, 24 | -1.66 Decreased by -348.65% | -3.23 Increased by +48.61% |
| Jan 31, 24 | -2.15 Decreased by -367.39% | -2.88 Increased by +25.35% |
| Nov 8, 23 | -0.27 Increased by +43.75% | -0.23 Decreased by -17.39% |
| Aug 9, 23 | -0.32 Increased by +37.25% | -0.29 Decreased by -10.34% |
| May 4, 23 | -0.37 Increased by +22.92% | -0.35 Decreased by -5.71% |
| Mar 22, 23 | -0.46 Decreased by -21.05% | -0.45 Decreased by -2.22% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 6.84 M Increased by +N/A% | -9.61 M Increased by +33.34% | Decreased by -140.44% Decreased by N/A% |
| Jun 30, 24 | 8.53 M Increased by +N/A% | -11.15 M Increased by +34.00% | Decreased by -130.69% Decreased by N/A% |
| Mar 31, 24 | 5.79 M Increased by +N/A% | -9.08 M Increased by +50.51% | Decreased by -156.91% Decreased by N/A% |
| Dec 31, 23 | 7.16 M Increased by +N/A% | -10.96 M Increased by +49.32% | Decreased by -153.04% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -14.42 M Increased by +37.00% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -16.90 M Increased by +30.61% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -18.34 M Increased by +20.33% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 22 | 0.00 Decreased by N/A% | -21.63 M Increased by +64.11% | Decreased by N/A% Decreased by N/A% |